You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: June 16, 2025

Drugs in MeSH Category Antineoplastic Agents


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Accord Hlthcare ERLOTINIB HYDROCHLORIDE erlotinib hydrochloride TABLET;ORAL 211083-001 Jul 2, 2020 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Hikma EVEROLIMUS everolimus TABLET;ORAL 206133-001 Apr 12, 2018 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Endo Operations EVEROLIMUS everolimus TABLET;ORAL 205775-002 Oct 18, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Theravia SIKLOS hydroxyurea TABLET;ORAL 208843-002 Dec 21, 2017 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Hikma ABIRATERONE ACETATE abiraterone acetate TABLET;ORAL 208339-001 Oct 31, 2018 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Accord Hlthcare PEMETREXED DISODIUM pemetrexed disodium SOLUTION;INTRAVENOUS 214408-004 Jul 19, 2022 RX Yes Yes ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Antineoplastic Agents Market Analysis and Financial Projection

The global market for anti-neoplastic agents is experiencing robust growth, driven by rising cancer prevalence and technological innovations, while a dynamic patent landscape reflects intense competition and strategic IP maneuvers. Here's a detailed analysis:


Market Dynamics

Growth Projections and Valuation

  • The anti-neoplastic pharmaceutical agents market was valued at $10.1 billion in 2022, projected to reach $28.8 billion by 2032 at an 11% CAGR [1].
  • Broader anti-neoplastic agents (including non-pharmaceutical categories) reached $108 billion in 2021 and are expected to hit $233 billion by 2028 (7.5% CAGR) [6][13].
  • Oncology drugs, a key segment, are forecasted to grow from $202.3 billion in 2023 to $530.4 billion by 2032, driven by targeted therapies and immunotherapies [12].

Key Growth Drivers

  1. Rising Cancer Incidence: Over 238,000 new lung cancer cases in the U.S. in 2023 alone highlight demand [10].
  2. Technological Advancements: Innovations in mRNA therapeutics (e.g., lipid nanoparticle delivery systems) and nanotechnology (polymer/protein-based nanoparticles) enhance treatment efficacy [4][11][14].
  3. Government Initiatives: Policies supporting affordable cancer care and R&D investments accelerate market expansion [1][6].

Market Restraints

  • High Treatment Costs: Monthly prices for targeted therapies remain prohibitive in many regions [8].
  • Awareness Gaps: Limited understanding of neoplasm symptoms in developing nations delays diagnosis and treatment [1].

Patent Landscape

Strategic Patenting Trends

  1. Formulation Innovations:

    • Patent 6,987,108 (Schering Corp.) covers dissolvable formulations of antineoplastic agents using urea or amino acids [2].
    • Patent 6,838,464 (AstraZeneca) protects pyrimidine derivatives as inhibitors of CDK/FAK kinases, critical for cell cycle regulation [7].
  2. Delivery Systems:

    • mRNA cancer therapeutics dominate with 650+ patents held by leaders like Moderna (lipid nanoparticles) and Pfizer (mRNA stability enhancements) [4].
    • Nanoparticle patents focus on polymers and proteins to improve drug targeting and reduce side effects [11][14].
  3. Evergreening Tactics:

    • Originators extend exclusivity via secondary patents (e.g., method-of-use claims). Example: Celgene prolonged market monopoly for a drug by patenting combination therapies [9].

Regional Patent Activity

  • U.S. Dominance: 350+ mRNA patents due to regulatory flexibility and R&D investment [4].
  • Europe and Asia: 250 and 150 mRNA patents, respectively, driven by collaborative research and government funding [4].

Competitive and Regulatory Landscape

Key Players

  • Top Innovators: Roche, Pfizer, Novartis, and Johnson & Johnson lead with portfolios spanning biologics, small molecules, and biosimilars [6][12].
  • Biosimilar Challenges: Expiring biologics patents (e.g., trastuzumab) face litigation, delaying generics. However, biosimilars are gaining traction with new formulations [5].

Emerging Opportunities

  • Personalized Medicine: mRNA therapies enable tailored treatments, with self-amplifying vaccines holding 400+ patents for enhanced immune responses [4].
  • Nanotechnology: Over 14 years of patent filings highlight nanoparticles as a priority for improving drug solubility and tumor targeting [11][14].

Future Outlook

The market will hinge on balancing innovation with affordability. While evergreening and high costs pose barriers, advancements in nanotechnology, mRNA platforms, and biosimilars promise transformative outcomes. Collaborative IP strategies and regulatory reforms will shape accessibility, particularly in emerging economies.

"The extended monopoly for originator drugs, averaging 28 years, underscores the need for policies that encourage competition without stifling innovation." [9]


Key Takeaways

  • Anti-neoplastic markets are expanding rapidly due to unmet clinical needs and R&D breakthroughs.
  • Patent strategies increasingly focus on delivery mechanisms and secondary uses to prolong exclusivity.
  • Nanotechnology and mRNA platforms represent the next frontier in oncology therapeutics.

References

  1. https://www.futuremarketinsights.com/reports/anti-neoplastic-pharmaceutical-agents-market
  2. https://www.drugpatentwatch.com/p/patent/6987108
  3. https://meshb.nlm.nih.gov/record/ui?ui=D000964
  4. https://www.globenewswire.com/news-release/2025/03/11/3040828/28124/en/mRNA-Cancer-Therapeutics-Patent-Landscape-Report-and-Forecast-2024-2032-Featuring-Pfizer-Moderna-and-Novartis-with-650-Patents-Combined.html
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7188399/
  6. https://www.fnfresearch.com/anti-neoplastic-agents-market
  7. https://www.drugpatentwatch.com/p/patent/6838464
  8. https://pubmed.ncbi.nlm.nih.gov/21606435/
  9. http://bulletin.mfd.org.mk/volumes/Volume%2068_3/68_3_254.pdf
  10. https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report
  11. https://plus.cobiss.net/cobiss/adz/en/discovery/eNo1j8tKw0AUQAdRbKld-AMyP5A4c3Pn5U6LLyi60XW5mdxKJE2GzHTh31sQdwcOHDhCXGtVozbmNiWqNdbozsQSFNrKBwsLsc75WymlNTgf_KVYgEEfgsaleHijcUo0lz4OnCWlNPTcyTJJGks_8pQGyicp6YvHku8kyUTlhHKgscuREl-Jiz0NmdfivMxHXonPp8ePzUu1fX9-3dxvqwjelCqERocWIvlonY5gA0eHTlnjFPpm32Gj2uicQYvsG44KggOrW9cxggFYiZu_bjq2B-52ae4PNP_s_l_gF131SIE
  12. https://www.globenewswire.com/news-release/2025/03/17/3043832/0/en/Oncology-Drugs-Market-Size-to-Surpass-USD-530-39-Billion-by-2032-Driven-by-Advancements-in-Targeted-Therapies-and-Rising-Cancer-Incidence-SNS-Insider.html
  13. https://www.researchandmarkets.com/reports/5931024/anti-neoplastic-agents-global-market-report
  14. https://vpinstitute.org/nanoparticles-applied-to-antineoplastic-agents-a-patent-landscape/
Last updated: 2025-03-25

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.